We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Latest Generation Coagulation Monitor Boasts Built-in WI-FI Connectivity

By LabMedica International staff writers
Posted on 13 Dec 2015
A new coagulation monitor for professional use combines two critical assays—the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test—in a single small, portable instrument.

The medical equipment manufacturer Roche (Basel, Switzerland) recently announced the launch of the CoaguChek Pro II system in countries accepting the CE marking for diagnostic tools. More...
CoaguChek Pro II combines two tests in a single device for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms, intensive care units, or anticoagulation clinics.

The instrument is small and portable, requiring only a small sample volume of eight microliters to run a full test, and accepts different blood sample types, including capillary blood from a finger prick as well as venous and arterial whole blood. Accuracy and precision of the test strips are guaranteed, since each lot of the test strips is precalibrated against the World Health Organization (WHO) reference method.

The instrument boasts built-in WI-FI connectivity, which allows test results to be transmitted automatically in real time to patients’ electronic health records, ensuring that vital information is immediately available at every point of care.

“Building on the best in class quality, CoaguChek Pro II is small, light, and convenient with accuracy and precision that our customers have come to expect from CoaguChek over the past 20 years,” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “As the latest addition to the CoaguChek family, CoaguChek Pro II expands our coagulation point of care offering beyond self-monitoring and doctors’ offices to also include more specialized settings such as the ER and OR.”

Related Links:

Roche



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.